Announcements Trials

Browse Landscape

Status

Terminated 3 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 8 Salivary Gland Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Pathologic Complete Response 1 Hemangiosarcoma 1 Heart Failure 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Breast Cancer 1 HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 42 Fluorouracil 27 Capecitabine 24 pembrolizumab 21 S 1 (combination) 19 Paclitaxel 19 Leucovorin 16 Nivolumab 13 Docetaxel 13 sintilimab 12 Drug Therapy 12 tislelizumab 10 Trastuzumab 10 Cisplatin 10 Irinotecan 9 Bevacizumab 8 trastuzumab deruxtecan 7 spartalizumab 7 XELOX 7 Surgical Procedures, Operative 7 Radiotherapy 7 Hyperthermic Intraperitoneal Chemotherapy 7 Biopsy 7 fludarabine 6 disitamab vedotin 6 Cyclophosphamide 6 lenvatinib 5 apatinib 5 Specimen Handling 5 Ramucirumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Stomach Neoplasms × Ado-Trastuzumab Emtansine × Clear all

NCT07389876 2026-02-05

G/GEJ

Fudan University

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡